

www.apexbt.com



APE_xBIO

An Apoptosis and Epigenetics Company

Inhibitor Catalog 2015

**Small Molecule Compounds, Big
Biomedical Research**

Contents

 ApexBio Inhibitor Catalog 2015

A

- 01 ATM (Ataxia telangiectasia mutated)
- 02 Aurora Kinase
- 03 Autophagy

B

- 04 Bcl-2 (B-cell lymphoma 2)

C

- 05 Caspase
 - 06 CDK (Cyclin-dependent kinase)
 - 07 c-MET (Hepatocyte growth factor receptor)
-

E

- 08 EGFR (Epidermal growth factor receptor)

G

- 09 Gamma-secretase

H

- 10 HDAC (Histone deacetylase)
 - 11 Hsp (Heat shock protein)
-

J

- 12 JAK (Janus kinase)

M

- 13 MEK (Mitogen-activated protein kinase kinase)
- 14 mTOR (Mechanistic target of rapamycin)

P

- 15 p53 (Tumor protein p53)
 - 16 PARP (Poly ADP-ribose polymerase)
 - 17 PI3K/Akt (Phosphoinositide 3-kinase/protein kinase B)
 - 18 PPAR (Peroxisome proliferator-activated receptor)
 - 19 Proteasome
-

V

- 20 VEGFR (Vascular endothelial growth factor)


W

- 21 Wnt (Wingless-type MMTV integration site family)

More

- 23 Hot Products
 - 33 Worldwide Distributer
-

Publications Citing ApexBio Products



2015,160(4):729-744.




2015, May;17(5):627-38.



2014,111(26):9503-8.




2015, Aug, 12



2015 May 29. Epub.



2014,5(11):3728-42.



2014,7(357):ra122.



2015,17(4):403-413.



2015,194(4):1763-75.




2014,193(7):3577-89.




2015,359(2):250-258.



2015 Jul 2;14(7):2839-48



2014,13(12):5461-70.



2015,36(3):1462-1470.



2014 Apr 2. Epub




2015 Jun;7(4):641-52.

Publications Citing ApexBio Products



2015 Jun 22. Epub



2015,290(14):8722-8733.



2014,289(39):27246-63.




2014,34(23):4216-31.



2015,143(2):441-53



2015,24(6):781-90.




2015,150(1):105-118.



2015,110:36-34.




2015 Jan;46(1):395-406.




2015,83(4):789-795.



2015,5(3):287.



2015,98(2):277-285.




2014,23(1):288-93.



2015 May;36(5):606-13.




2015,75(2):411-420.



2015,458(3):656-662.

ATM Signaling Pathway




Hot products in ATM signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A3210	AZ20	ATR (IC50=5 nM)	Inhibitor	Selective	23394205; J. Med. Chem.; 2013		
B1383	VE-822	ATR (IC50=0.019 μM)	Inhibitor	Selective	23222511; Cell Death Dis.; 2012		
A8626	ETP-46464	ATR (IC50=14 nM) ATM (IC50=545 nM)	Inhibitor	Selective	24799566; J Immunol.; 2014		
A8625	CP-466722	ATM	Inhibitor	Selective	18794134; Cancer Res.; 2008		
A8624	CGK733	ATM (IC50=200 nM) ATR (IC50=200 nM)	Inhibitor	Selective	16767085; Nat Chem Biol.; 2006		
A8336	KU-60019	ATM (IC50=6.3 nM)	Inhibitor	Selective	23620409; Clin Cancer Res.; 2013		
A4605	KU 55933	ATM (IC50=13 nM) ATR (K _i =2.2 nM)	Inhibitor	Selective	20053781; Mol Cancer Ther.; 2010		
A2521	VE-821	ATR (IC50=26 nM)	Inhibitor	Selective	21490603; Nat Cell Biol.; 2011		
B5389	Mirin	ATM (IC50 = 12 μM)	Inhibitor	Selective	18176557; Nat Chem Biol.; 2008		

For more product information, please check our website of "<http://www.apexbt.com/research-area/dna-damage/atm-kinase.html>".

Aurora Kinase Signaling Pathway




Hot products in Aurora Kinase signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4117	AT9283	Aurora A (IC50=3 nM) Aurora B (IC50=3 nM)	Inhibitor	Selective	25370467; Clin Cancer Res.; 2015		
A4120	MK-5108 (VX-689)	Aurora A (IC50=0.064 nM) Aurora B (IC50=14 nM) Aurora C (IC50=12 nM)	Inhibitor	Selective	23955083; Oncogene; 2014		
A4122	PHA-680632	Aurora A (IC50=27 nM) Aurora B (IC50=135 nM) Aurora C (IC50=120 nM)	Inhibitor	Pan	23974204; Blood; 2013		

For more product information, please check our website of <http://www.apexbt.com/research-area/cell-cycle/aurora-kinase-a.html>.

Autophagy Signaling Pathway




Hot products in Autophagy signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4083	Rocilinostat (ACY-1215)	HDAC6 (IC50=5 nM)	Inhibitor	Selective	25458911; J Allergy Clin Immunol.; 2015	Phase 1	Relapsed/Refractory Lymphoid Malignancies
A8631	FK 866 hydrochloride	NAMPT (IC50 = 0.09 nM)	Inhibitor	Selective	23221771; Autophagy; 2013		
A8630	Xanthohumol	VCP	Inhibitor	Selective	25887885; Mol Cancer Ther.; 2015	Phase 1	Oxidative Stress
A8629	DBE-Q	P97 (IC50 = 1.5 μM)	Inhibitor	Selective	21606684; Autophagy; 2011		
A8627	Bafilomycin A1	V-ATPase	Inhibitor	Selective	25906314; Autophagy ; 2015		
A2845	Omeprazole	H ⁺ ,K ⁺ -ATPase	Inhibitor	Selective	21345487; 21345487; 2011	FDA Approved	
A8353	3-Methyladenine	Vps34 (IC50=25 μM); PI3Kγ (IC50=60 μM)	Inhibitor	Selective	25996656; Autophagy; 2015		
A8487	Nocodazole	Abi (IC50=0.21 μM); Abi (E255K) (IC50=0.53 μM); Abi (T315) (IC50=0.64 μM);	Inhibitor	Pan	24519927; Circulation; 2014		
A8544	Wortmannin	PI3K (IC50=3nM)	Inhibitor	Selective	26043790; Autophagy; 2015		
A4393	Paclitaxel (Taxol)	Microtubule (IC50 = 0.1 pM)	Activator	Selective	25564897; N Engl J Med.; 2015	FDA Approved	
A8883	SAR405	Vps34	Inhibitor	Selective	25326666; Nat Chem Biol.; 2014		
A8633	Concanamycin A	V-ATPase	Inhibitor	Selective	25484071; Autophagy.; 2015		
A8250	LY 294002	PI3Kδ (IC50=0.57 nM)	Inhibitor	Selective	23958920; Leukemia. 2014		

For more product information, please check our website of "<http://www.apexbt.com/research-area/ubiquitination/autophagy.html>".

Bcl-2 Signaling Pathway




Hot products in Bcl-2 signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A3935	WEHI-539	Bcl-xL (IC50 = 1.1 nM)	Inhibitor	Selective	23603658; Nat Chem Biol. ; 2013		
A4234	TW-37	Bcl-2 (Ki = 0.29 μM); Bcl-xL (Ki = 1.11 μM); Mcl-1 (Ki = 0.26 μM)	Inhibitor	Pan	23832116; Cell Death Differ.; 2013		
A3007	ABT-263	Bcl-2 (Ki ≤ 1 nM); Bcl-xL (Ki ≤ 0.5 nM); Bcl-w (Ki ≤ 1 nM)	Inhibitor	Pan	23245996; Cancer Cell; 2013	Phase 2	Chronic Lymphocytic Leukemia
A8193	ABT-737	Bcl-2 (EC50 = 30.3 nM); Bcl-xL (EC50 = 78.7 nM); Bcl-w (EC50 = 197.8 nM)	Inhibitor	Pan	25715028; Autophagy; 2015	Phase 2	Ovarian Cancer
A8194	ABT-199	Bcl-2 (Ki < 0.01 nM)	Inhibitor	Selective	25599133; Nat Med; 2015	Phase 3	Chronic Lymphocytic Leukemia
A4199	Sabutoclax	Bcl-2 (IC50 = 0.32 μM); Bcl-xL (IC50 = 0.31 μM); Mcl-1 (IC50 = 0.2 μM)	Inhibitor	Pan	23333150; Cell Stem Cell; 2013		
N2135	Gossypol	Bcl-2; Bcl-xL	Inhibitor	Selective	23640104; Leukemia; 2013	Phase 3	Non-small Cell Lung Cancer
A8168	HA14-1	Bcl-2 (IC50 = 9 μM)	Inhibitor	Selective	23403318; Haematologica ; 2013		
A4200	Apogossypolone (ApoG2)	Bcl-2 (Ki = 35 nM); Bcl-xL (Ki = 660 nM); Mcl-1 (Ki = 25 nM)	Inhibitor	Pan	23392177; Cell Death Dis; 2013		
B4881	UMI-77	Mcl-1 (Ki = 490 nM)	Inhibitor	Selective	24019208; Mol Cancer Ther.; 2014		
B4901	Mcl-1	Mcl-1	Inhibitor	Selective	25585174; J Med Chem.; 2015		
A3218	BAM7	BAX (IC50 = 3.3 μM)	Activator	Selective	24748042; Plant Cell.; 2014		

For more product information, please check our website of "<http://www.apexbt.com/research-area/apoptosis/bcl-2-family.html>".

Caspase Signaling Pathway




Hot products in Caspase signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A1920	Z-DEVD-FMK	Caspase-3/-2/-6/-7/-8/-10	Inhibitor	Pan	25596736; Oncotarget; 2015		
A1902	Z-VAD-FMK	Caspase	Inhibitor	Pan	23804706; Mol Cancer Ther; 2013		
A8321	Cisplatin	Caspase-3	Activator	Selective	26045340; Lancet Oncol.; 2015	FDA Approved	
B3232	Z-IETD-FMK	Caspase-8	Inhibitor	Selective	25596736; Oncotarget; 2015		
A8238	VX-765	Caspase-1 (Ki=0.8 nM)	Inhibitor	Selective	21431948; Neurotherapeutics.; 2011	Phase 2	Partial Epilepsy
A3424	Gambogic Acid	Caspase-3 (EC50=0.78-1.64 μM)	Activator	Selective	24334603; Clin Cancer Res.; 2014		
A1901	Q-VD-Oph hydrate	Caspase	Inhibitor	Pan	24457292; Stroke.; 2014		
A1904	Boc-D-FMK	Caspase	Inhibitor	Pan	19366808; Cancer Res. ; 2009		
A8170	Z-FA-FMK	Caspase	Inhibitor	Pan	18567942; Autophagy. 2008		
A1922	Z-VDVAD-FMK	Caspase-2	Inhibitor	Selective	18214855; Int J Cancer.; 2008		
A8177	PAC-1	Procaspase-3 (EC50 = 0.22 μM) Procaspase-7 (EC50 = 4.5 μM)	Activator	Selective	24383395 ; J Am Chem Soc. 2014	Phase 1	Advanced Malignancies
B3233	Z-LEHD-FMK	Caspase-8	Inhibitor	Selective	25066695; J Mol Cell Cardiol.; 2014		

For more product information, please check our website of "<http://www.apexbt.com/research-area/peptidases/caspase.html>".

CDK Signaling Pathway




Hot products in CDK signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A3417	Flavopiridol	CDK1 (IC50=40nM) ; CDK2 (IC50=40nM) ; CDK4(IC50=40nM)	Inhibitor	Pan	24662513; Nat Commun. ; 2014	Phase 2	Lymphoma
A5719	AT7519	CDK2/cyclin A(IC50=47nM); CDK4/cyclin D1(IC50=100nM); CDK5/p35(IC50=13nM)	Inhibitor	Pan	21325451; Ann Oncol.; 2011	Phase 2	Mantle Cell Lymphoma
A1980	SNS-032	CDK2(IC50=48nM); CDK7(IC50=62nM); CDK9(IC50=4nM)	Inhibitor	Selective	21212792;Leukemia.; 2011	Phase 1	Advanced B-lymphoid Malignancies
B3277	AMG 925	CDK4(IC50=3nM)	Inhibitor	Selective	25487917; Mol Cancer Ther. ; 2015		
A8565	Purvalanol B	CDK1; CDK2; CDK4	Inhibitor	Pan	25296977; Oncotarget.; 2014		
B8002	LY2857785	CDK9(IC50 = 11 nM)	Inhibitor	Selective	24688048; Mol Cancer Ther. 2014		

For more product information, please check our website of "<http://www.apexbt.com/research-area/cell-cycle/cyclin-d-kinase.html>".

c-MET Signaling Pathway




Hot products in c-MET signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A8325	Tivantinib (ARQ 197)	c-Met (Ki=0.355uM)	Inhibitor	Selective	23182627; Lancet Oncol. ;2013	Phase 3	Relapsed/Refractory Lymphoid Malignancies
A5092	JNJ-38877605	c-Met (IC50=4nM)	Inhibitor	Selective	25745036; Clin Cancer Res. ; 2015	Phase 1	
A5096	PF-04217903	c-Met (IC50=4.8nM)	Inhibitor	Selective	26013381; Nat Commun. ; 2015	Phase 1	Oxidative Stress
A2307	PHA-665752	c-Met (IC50=9nM)	Inhibitor	Selective	24615768; Int J Cancer. ; 2014		
A2678	SU11274	c-Met (IC50=10nM)	Inhibitor	Selective	24327519; Mol Cancer Ther. ; 2014		
A5703	BMS-777607	c-Met (IC50=3.9nM)	Inhibitor	Selective	24444656; Mol Oncol. ; 2014	Phase 2	
A2977	Cabozantinib (XL184, BMS-907351)	c-Met (IC50=1.3nM)	Inhibitor	Selective	25971939; Cancer Discov. ; 2015	Phase 4	
A3020	(R)-Crizotinib	c-Met (IC50=11nM)	Inhibitor	Selective	25693023; N Engl J Med. ; 2015	Phase 4	
B1439	Golitinib	c-Met (IC50=14nM)	Inhibitor	Selective	25278451; Clin Cancer Res. ; 2014		
A3573	LY2801653	c-Met (Ki=2nM)	Inhibitor	Selective	24305878; Cancer Res. ; 2014	Phase 1	
A3388	EMD-1214063	c-Met (IC50=4nM)	Inhibitor	Selective	23553846; Clin Cancer Res. ; 2013	Phase 1	

For more product information, please check our website of "<http://www.apexbt.com/research-area/tyrosine-kinase/c-met.html>".

EGFR Signaling Pathway




Hot products in EGFR signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
B1493	AG-490 (Tyrosinostin B42)	EGFR (IC50=0.1 μ M);	Inhibitor	Selective	24619965; Hepatology; 2014		
A8322	Neratinib (HKI-272)	EGFR (IC50=92nM); HER2 (IC50=59nM)	Inhibitor	Selective	25287822; J Clin Oncol.; 2014	Phase 3	Breast Cancer
A8319	Dacomitinib (PF299804, PF299)	EGFR (IC50=6nM); HER2(IC50=45.7nM); HER4(IC50=73.7 nM)	Inhibitor	Pan	25456362; Lancet Oncol.; 2014	Phase 3	Lung Cancer
B1104	AZD-9291	EGFR (IC50=493.8 nM); Exon 19 deletion EGFR (IC50=12.92 nM); L858R/T790M EGFR (IC50=11.44 nM)	Inhibitor	Selective	25923549; N Engl J Med.; 2015	Phase 3	Non-small Cell Lung Cancer
B1496	Icotinib	EGFR (IC50=5nM); L858RnInhibitor /T790M EGFR(IC50=5nM); T790M EGFR (IC50=5nM)	Inhibitor	Pan	23948351; Lancet Oncol.;	Phase 4	Non-small Cell Lung Cancer
A8247	Afatinib (BIBW2992)	EGFR (IC50=0.5nM); HER2 (IC50=14nM); L858R EGFR (IC50=0.4nM)	Inhibitor	Pan	26051236; Lancet Oncol.; 2015	FDA Approved	
A3320	CO-1686 (AVL-301, Rocicetinib)	EGFR (IC50=303.3nM); L858R/T790M EGFR (IC50=21.5nM);	Inhibitor	Selective	25923550; N Engl J Med.; 2015	Phase 3	Non-small Cell Lung Cancer
A8218	Lapatinib	EGFR (IC50=10.8nM); HER2 (IC50=9.2nM)	Inhibitor	Selective	25130998; Lancet Oncol.; 2015	FDA Approved	
A3256	BMS-690514	EGFR (IC50=5nM); HER2 (IC50=19nM)	Inhibitor	Pan	23490650; Eur J Cancer. 2013	Phase 2	Non-small Cell Lung Cancer

For more product information, please check our website of "<http://www.apexbt.com/research-area/jak-stat-signaling/egfr.html>".

Gamma Secretase Signaling Pathway




Hot products in Gamma Secretase signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A8200	DAPT (GSI-IX)	γ-secretase[Aβ] (IC50=20nM)	Inhibitor	Selective	24502949; BBRC; 2014		
A4022	BMS-708163 (Avagacestat)	γ-secretase[Aβ40] (IC50=0.3nM); γ-secretase [Aβ42] (IC50=0.27nM)	Inhibitor	Selective	23018531; Clin Pharmacokinet.; 2012	Phase 2	Alzheimer's Disease
A4006	MK-0752	γ-secretase (IC50=5nM)	Inhibitor	Pan	22547604; J Clin Oncol.; 2012	Phase 2	Metastatic Breast Cancer
A4018	YO-01027 (Dibenzazepine, DBZ)	γ-secretase [APP] (IC50=2.6nM) ; γ-secretase [Notch] (IC50=2.9nM)	Inhibitor	Selective	25500886; J Clin Invest.; 2015		
A3711	PF-03084014	γ-secretase(IC50=6.2nM)	Inhibitor	Pan	24781018; Leukemia.; 2015	Phase 2	Desmoid Tumors; Aggressive Fibromatosis
A4405	MRK -560	γ-secretase[Aβ40] (IC50=0.65nM); γ-secretase [Aβ42] (IC50=0.65nM)	Inhibitor	Selective	23197721; J Neurosci.; 2012		
A4005	RO4929097	γ-secretase (IC50=4nM); γ-secretase [Aβ40](IC50=14nM); γ-secretase [Notch](IC50=5nM)	Inhibitor	Pan	25339752; J Neurosci.; 2014	Phase 2	Pancreatic Cancer; Colon Cancer

For more product information, please check our website of "<http://www.apexbt.com/research-area/proteases/gamma-secretase.html>".

HDAC Signaling Pathway




Hot products in HDAC signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
B1251	Valproic acid	HDAC1 (IC50 =0.4mM)	Inhibitor	Selective	25707399; Mol Psychiatry.; 2015	Phase 4	Bipolar Disorder
A4104	AR-42 (OSU-HDAC42)	HDAC (IC50=30 nM)	Inhibitor	Pan	25273096; Sci Transl Med.; 2014	Phase 1	Acute Myeloid Leukemia
A4101	Tubastatin A	HDAC6 (IC50=15 nM)	Inhibitor	Selective	24146251; Circulation.; 2014		
A4501	Tubacin	HDAC6 (IC50=4 nM)	Inhibitor	Selective	25751058; Nat Biotechnol.; 2015		
A4090	JNJ-26481585	HDAC1 (IC50=0.11 nM); HDAC2 (IC50=0.33 nM); HDAC11 (IC50=0.37 nM)	Inhibitor	Pan	23741066; Clin Cancer Res.; 2013	Phase 2	Previously Treated Stage Ib-Iva Cutaneous T-cell Lymphoma
A4089	Mocetinostat (MGC0103, MG0103)	HDAC1 (IC50=0.15 µM); HDAC2 (IC50=0.29 µM); HDAC3 (IC50=1.66 µM)	Inhibitor	Pan	25872941; EMBO Mol Med.; 2015	Phase 2	Refractory Chronic Lymphocytic Leukemia
A8173	Romidepsin (FK228, depsipeptide)	HDAC1 (IC50=36 nM); HDAC2 (IC50=47 nM)	Inhibitor	Selective	25118879; Leukemia.; 2015	FDA Approved	
A8183	Trichostatin A(TSA)	HDAC (IC50=1.8 nM)	Inhibitor	Pan	24792117; Cell Stem Cell.; 2014		
A8178	Panobinostat (LBH589)	HDAC	Inhibitor	Pan	25939062; Nat Med.; 2015	FDA Approved	
A8171	Entinostat (MS-275, SNDX-275)	HDAC1 (IC50=0.51 µM); HDAC3 (IC50=1.7 µM)	Inhibitor	Selective	25030697; Genes Dev.; 2014	Phase 2	Metastatic Colorectal Cancer
A4092	CUDC-101	HDAC1 (IC50=4.5 nM); HDAC5 (IC50=11.4 nM); HDAC6 (IC50=5.1nM)	Inhibitor	Pan	25573383; Clin Cancer Res.; 2015	Phase 1	Cancer

For more product information, please check our website of "<http://www.apexbt.com/genesearch/result/?q=HDAC1>".

HSP Signaling Pathway




Hot products in HSP signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4054	17-AAG (KOS953)	Hsp90 (5 nM)	Inhibitor	Pan	21315436; Cell; 2011	Phase 2	Lymphoma; Kidney Cancer
A3739	PU-H71	Hsp90 (51 nM)	Inhibitor	Pan	19966776; Nat Med; 2009	Phase 1	Lymphoma
A4061	IPI-504 (Retaspimycin hydrochloride)	Hsp90 (N/A)	Inhibitor	Pan	21907929; Cancer Cell; 2011	Phase 2	Prostate Cancer; non-small cell lung cancer (NSCLC)
B7393	Gedunin	Hsp90 (N/A)	Inhibitor	Pan	17010675; Cancer Cell; 2006		
A2213	17-DMAG (Alvespimycin) HCl	Hsp90 (62 ± 29 nM)	Inhibitor	Pan	22105779; Hepatology; 2012	Phase 1	Lymphoma; Breast Cancer
A4057	AUY922 (NVP-AUY922)	Hsp90α (13 nM); Hsp90β (21 nM)	Inhibitor	Selective	25870087; J Clin Oncol; 2015	Phase 2	Breast Cancer; Non-small-cell Lung Cancer
A4060	Geldanamycin	Hsp90 (N/A)	Inhibitor	Pan	17671417; Autophagy; 2007	Phase 2	Kidney Cancer
A3161	Alvespimycin	Hsp90 (62 nM)	Inhibitor	Selective	22105779; Hepatology; 2012	Phase 1	Lymphoma; Breast Cancer
A4067	Radicicol	Hsp90 (<1 μM)	Inhibitor	Pan	17615388; Am J Respir Crit Care Med; 2007		
A4385	Ganetespib (STA-9090)	Hsp90 (4 nM)	Inhibitor	Pan	23533265; Cancer Discov; 2013	Phase 3	Non-Small-Cell Lung Adenocarcinoma
A4386	Elesclmolol (STA-4783)	Hsp70 (N/A)	Activator	Selective	23401447; J Clin Oncol; 2013	Phase 2	Soft Tissue Sarcomas; Non Small Cell Lung Cancer (NSCLC)
A4065	PF-04929113 (SNX-5422)	Hsp90 (50 nM)	Inhibitor	Selective	24411988; Eur Urol; 2014	Phase 1	Refractory Solid Tumor Malignancies; Hematologic Neoplasms

For more product information, please check our website of "<http://www.apexdt.com/research-area/metabolism/hsp.html>".

JAK/STAT Signaling Pathway




Hot products in JAK/STAT signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
B1259	(3R,4S)-Tofacitinib	JAK1 (IC50=112 nM); JAK2 (IC50=20 nM); JAK3 (IC50=1 nM)	Inhibitor	Selective	26051365; Lancet; 2015	Phase 4	Rheumatoid Arthritis
A4138	Tofacitinib (CP-690550, Tasocitinib)	JAK1 (IC50=112 nM); JAK2 (IC50=20 nM); JAK3 (IC50=1 nM)	Inhibitor	Selective	26051365; Lancet; 2015	FDA approved	
A3012	Ruxolitinib (INCB018424)	JAK1 (IC50=3.3 nM); JAK2 (IC50=2.8 nM)	Inhibitor	Selective	25629741; N Engl J Med; 2015	FDA approved	Oxidative Stress
A4149	S-Ruxolitinib (INCB018424)	JAK1 (IC50=3.3 nM); JAK2 (IC50=2.8 nM); JAK3 (IC50=428 nM)	Inhibitor	Selective	25629741; N Engl J Med; 2015	Phase 4	Myelofibrosis (PMF); Splenomegaly
A4136	TG101348 (SAR302503)	JAK2 (IC50=3 nM)	Inhibitor	Selective	18394555; Cancer Cell; 2008	Phase 3	Myelofibrosis
A4137	AZD1480	JAK2 (IC50=0.26 nM)	Inhibitor	Selective	21164517; Leukemia; 2011	Phase 1	Myeloproliferative Diseases
A4143	CYT387	JAK1 (IC50=11 nM); JAK2 (IC50=18 nM); JAK3 (IC50=155 nM)	Inhibitor	Selective	25365225; J Clin Invest; 2014	Phase 3	Myelofibrosis
A4145	TG101209	JAK2 (IC50=6 nM); JAK3 (IC50=169 nM)	Inhibitor	Selective	23812420; Leukemia; 2013		
A4513	Lestauritinib	JAK2 (IC50=0.9nM)	Inhibitor	Selective	16761017; Leukemia; 2006	Phase 3	Acute Undifferentiated Leukemia
A4512	Cucurbitacin I	JAK2 (N/A)	Inhibitor	Selective	22441021; Autophagy; 2012		
A3794	SB1317	JAK2 (IC50 = 73 nM)	Inhibitor	Selective	21860433; Leukemia; 2012		

For more product information, please check our website of "<http://www.apexbt.com/research-area/jak-stat-signaling/jak2.html>".

MEK1/2 Signaling Pathway




Hot products in MEK1/2 signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A3018	Trametinib (GSK1120212)	MEK1 (IC50=0.92 nM); MEK2 (IC50=1.8 nM)	Inhibitor	Selective	26037941; Lancet; 2015	FDA approved	
A3321	Cobimetinib	MEK (N/A)	Inhibitor	Pan	25265494; N Engl J Med; 2014	Phase 3	Melanoma
A8207	AZD6244 (Selumetinib)	MEK1 (IC50=14 nM)	Inhibitor	Selective	23406027; N Engl J Med; 2013	Phase 3	Metastatic
A1947	MEK162 (ARRY-162, ARRY-438162)	MEK1/2 (IC50=12 nM)	Inhibitor	Selective	23414587; Lancet Oncol; 2013	Phase 3	Melanoma; Ovarian Cancer
A1663	PD98059	MEK1 (IC50=10 μM)	Inhibitor	Selective	15316530; J Allergy Clin Immunol; 2004		
A3013	PD0325901	MEK1/2 (IC50=0.33 nM)	Inhibitor	Selective	23221341; J Clin Invest; 2013	Phase 2	Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
A1792	PD184352 (CI-1040)	MEK (Ki=300 nM)	Inhibitor	Pan	21483442; Leukemia; 2011	Phase 2	Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
N2399	Arctigenin	MEK1 (IC50=0.5nM)	Inhibitor	Selective	16452235; Cancer Res; 2006		
A5573	Pimasertib (AS-703026)	MEK1/2 (IC50=5 nM-2 μM)	Inhibitor	Selective	21118963; Cancer Res; 2011	Phase 2	Cutaneous Melanoma; Ovarian Cancer
B7124	PD 198306	MEK1/2 (N/A)	Inhibitor	Selective	12794826; Arthritis Rheum; 2003		
B1267	Refametinib	MEK1 (IC50=19 nM); MEK2 (IC50=47 nM)	Inhibitor	Selective	25294897; Clin Cancer Res; 2014	Phase 2	RAS Mutant Hepatocellular Carcinoma

For more product information, please check our website of "<http://www.apexbt.com/research-area/mapk/mek1-2.html>".

mTOR Signaling Pathway




Hot products in mTOR signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A8169	Everolimus (RAD001)	mTOR (IC50=1.6-2.4 nM)	Inhibitor	Pan	23158522; Lancet; 2013	FDA approved	
A8167	Rapamycin (Sirolimus)	mTOR (IC50=0.1 nM)	Inhibitor	Pan	8717522; Annu Rev Immunol; 1996	FDA approved	
A8314	Temsirolimus	mTOR (IC50=1.76 μM)	Inhibitor	Pan	17538086; N Engl J Med; 2007	FDA approved	
A3664	Nordihydroguaiaretic acid	mTOR1 (N/A)	Inhibitor	Selective	21858850; Hepatology; 2011		
A8551	INK 128 (MLN0128)	mTOR (IC50=1 nM)	Inhibitor	Pan	22367541; Nature; 2012	Phase 2	Thyroid Cancer; Prostate Cancer; Breast Cancer
A8312	Torin 1	mTOR1 (IC50=2 nM); mTOR2 (IC50=10 nM)	Inhibitor	Selective	22552098; Nature; 2012		
A8318	PP242	mTOR (IC50=8 nM)	Inhibitor	Pan	20072130; Nat Med; 2010		
A8214	AZD8055	mTOR (IC50=0.8 nM)	Inhibitor	Pan	24163374; Cancer Discov; 2014	Phase 1	Solid Tumors; Glioblastoma Multiforme
B1639	Ridaforolimus (Deforolimus, MK-8669)	mTOR (IC50=0.2 nM)	Inhibitor	Pan	26077241; J Clin Oncol; 2015	Phase 3	Metastatic Soft-Tissue Sarcomas
B1637	OSI-027	mTOR1 (IC50=22 nM); mTOR2 (IC50=65 nM)	Inhibitor	Selective	20699667; Autophagy; 2010	Phase 1	Solid Tumors; Lymphoma
A8373	AZD2014	mTOR (IC50=2.8 nM)	Inhibitor	Pan	25805799; Clin Cancer Res; 2015	Phase 2	Non-small Cell Lung Cancer Metastatic; Metastatic Breast Cancer; Gastric Adenocarcinoma

For more product information, please check our website of "<http://www.apexbt.com/research-area/pi3k-akt-signaling/mTOR-signaling.html>".

p53 Signaling Pathway




Hot products in p53 signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4206	Pifithrin- α (PFT α)	p53 (N/A)	Inhibitor	Pan	19475672; Ann Neurol; 2009		
A4455	Piperlongumine	p53 (N/A)	Activator	Pan	21753854; Nature; 2011		
A4483	PRIMA-1	p53 (N/A)	Activator	Pan	19411067; Cancer Cell; 2009		
A3762	RG7112	p53 (N/A)	Activator	Pan	23084521; Lancet Oncol; 2012	Phase 1	Neoplasms
A4202	RITA (NSC 652287)	MDM2/p53 (N/A)	Inhibitor	Selective	15558054; Nat Med; 2004		
A4203	Tenovin-1	p53 (N/A)	Activator	Pan	18455128; Cancer Cell; 2008		
A4208	NSC 319726	p53 (IC50=8 nM)	Activator	Pan	22624712; Cancer Cell; 2012		
A4228	Nutlin-3	MDM2/p53 (IC50=90 nM)	Inhibitor	Pan	24240203; Leukemia; 2014		
A3671	Nutlin-3a chiral	MDM2 (IC50=0.09 μ M)	Inhibitor	Selective	23513067; Circulation; 2013		
A4482	Pifithrin- μ	p53 (N/A)	Activator	Pan	21674585; Ann Neurol; 2011		
A4484	PRIMA-1MET	p53 (N/A)	Activator	Pan	22965953; J Clin Oncol; 2012		
A4485	RETRA hydrochloride	p53 (N/A)	Activator	Pan	18424558; Proc Natl Acad Sci U S A; 2008		

For more product information, please check our website of "<http://www.apexbt.com/research-area/apoptosis/p53.html>".

PARP Signaling Pathway




Hot products in PARP signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4154	Olaparib (AZD2281, Ku-0059436)	PARP1 (IC50=5 nM); PARP2 (IC50=1 nM)	Inhibitor	Selective	22452356; N Engl J Med; 2012	FDA approved	
A4157	Iniparib (BSI-201)	PARP1 (N/A)	Inhibitor	Selective	21208101; N Engl J Med; 2011	Phase 2	Breast Cancer
A3617	MK-4827	PARP1 (IC50=3.8 nM); PARP2 (IC50=2.1 nM)	Inhibitor	Selective	23810788; Lancet Oncol; 2013	Phase 1	Solid Tumors; Hematologic Malignancies
A3002	ABT-888 (Veliparib)	PARP1 (Ki=5.2 nM); PARP2 (Ki=2.9 nM)	Inhibitor	Selective	25286857; Acta Crystallogr D Biol Crystallogr; 2014	Phase 3	Breast Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer
A3729	PJ34	PARP1 (IC50=20 nM)	Inhibitor	Selective	11786525; Circ Res; 2002		
A4158	AG-14361	PARP1 (Ki<5 nM)	Inhibitor	Selective	14709739; J Natl Cancer Inst; 2004		
A4156	Rucaparib (AG-014699, PF-01367338)	PARP1 (Ki=1.4 nM)	Inhibitor	Selective	21183737; J Natl Cancer Inst; 2011	Phase 3	Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
A4529	JW 55	TNKS1 (IC50=1.9 μM); TNKS2 (IC50=0.83 μM)	Inhibitor	Selective	22440753; Cancer Res; 2012		

For more product information, please check our website of <http://www.apexbt.com/research-area/dna-damage/dna-parp.html>.

PI3K-AKT Signaling Pathway




Hot products in PI3K-AKT signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A3005	CAL-101 (Idelalisib, GS-1101)	PI3Kδ (IC50=2.5 nM)	Inhibitor	Selective	24450857; N Engl J Med; 2014	FDA approved	
A8210	GDC-0941	PI3Kα (IC50=3 nM); PI3Kβ (IC50=33 nM); PI3Kδ (IC50=3 nM)	Inhibitor	Selective	25043004; Nature; 2014	Phase 2	Breast Cancer; Non-Squamous Non-Small Cell Lung Cancer
A2067	PI-103	PI3Kα (IC50=2 nM); PI3Kβ (IC50=3 nM); PI3Kδ (IC50=3 nM)	Inhibitor	Selective	16697955; Cancer Cell; 2006		
A8246	BEZ235 (NVP -BEZ235)	PI3Kα (IC50=4 nM); PI3Kγ (IC50=5 nM); PI3Kδ (IC50=7 nM)	Inhibitor	Selective	19029981; Nat Med; 2008	Phase 2	Pancreatic Neuroendocrine Tumors; Breast Cancer; Renal Cell Carcinoma
A5176	AS-605240	PI3Kα (IC50=60 nM); PI3Kγ (IC50=8 nM)	Inhibitor	Selective	25073791; J Exp Med; 2014		
A8250	LY 294002	PI3Kα (IC50=0.5 nM); PI3Kβ (IC50=0.97 nM); PI3Kδ (IC50=0.57 nM)	Inhibitor	Selective	23958920; Leukemia; 2014		
A3015	BKM120	PI3Kα (IC50=52 nM); PI3Kβ (IC50=166 nM); PI3Kδ (IC50=116 nM)	Inhibitor	Selective	24310736; Leukemia; 2014	Phase 3	Breast Cancer
N1841	Quercetin	PI3K (N/A)	Inhibitor	Pan	21610320; Autophagy; 2011	Phase 4	Obese
A1720	IPI-145 (INK1197)	PI3Kγ (IC50=19.6 nM); PI3Kδ (IC50=0.36 nM)	Inhibitor	Selective	25917267; Leukemia; 2015	Phase 3	Lymphoma
A2065	IC-87114	PI3Kδ (IC50=0.5 μM)	Inhibitor	Selective	20224070; Am J Respir Crit Care Med; 2010		
A8248	ZSTK474	PI3Kα (IC50=16 nM); PI3Kβ (IC50=44 nM); PI3Kδ (IC50=4.6 nM)	Inhibitor	Selective	16622124; J Natl Cancer Inst; 2006	Phase 1	Solid Malignancies
A2764	PIK-90	PI3Kα (IC50=11 nM); PI3Kγ (IC50=18 nM); PI3Kδ (IC50=58 nM)	Inhibitor	Selective	19014771; J Allergy Clin Immunol; 2008		

For more product information, please check our website of "<http://www.apexbt.com/research-area/pi3k-akt-signaling/pi3k-inhibitors.html>".

PPAR Signaling Pathway




Hot products in PPAR signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A4304	Rosiglitazone	PPAR γ (Kd=43 nM)	Activator	Selective	22540912; N Engl J Med; 2012	FDA Approved	
B2117	Pioglitazone	PPAR γ (EC50=0.69 μ M)	Activator	Selective	21428766; N Engl J Med; 2011	FDA Approved	
B1943	Fenofibrate	PPAR α (N/A)	Activator	Selective	20228404; N Engl J Med; 2010	FDA Approved	
B1947	Gemfibrozil	PPAR α (N/A)	Activator	Selective	11454380; Lancet; 2001	FDA Approved	
A3893	Troglitazone	PPAR γ (EC50=555 nM)	Activator	Selective	19923924; Autophagy; 2010	FDA Approved	
A4300	GW9662	PPAR α (IC50=32 nM); PPAR γ (IC50=3.3 nM); PPAR δ (IC50=2000 nM)	Inhibitor	Selective	21873987; Nat Med; 2011		
A4301	T0070907	PPAR γ (IC50=1 nM)	Inhibitor	Selective	17484875; Gastroenterology; 2007		
B7406	GSK 0660	PPAR δ (IC50=0.155 μ M)	Inhibitor	Selective	20693380; Am J Respir Crit Care Med; 2010		
A4309	GW501516	PPAR β (EC50=1.1 nM)	Activator	Selective	14758356; Nat Med; 2004	Phase 4	Metabolic Syndrome
A4307	GW0742	PPAR β (N/A); PPAR δ (EC50=1.1 nM)	Activator	Selective	21300064; Gastroenterology; 2011		
B6691	BADGE	PPAR γ (N/A)	Inhibitor	Selective	22763116; Environ Health Perspect; 2012		
A4303	GSK3787	PPAR β (pIC50=6.6); PPAR δ (pIC50=6.6)	Inhibitor	Selective	20128594; J Med Chem; 2010		
B6929	SR 202	PPAR γ (IC50=140 μ M)	Inhibitor	Selective	3612689; J Med Chem; 1987		

For more product information, please check our website of "<http://www.apexbt.com/research-area/metabolism/ppar.html>".

Proteasome Signaling Pathway




Hot products in Proteasome signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A2614	Bortezomib (PS-341)	20s proteasome (Ki=0.6 nM)	Inhibitor	Selective	25738670; N Engl J Med; 2015	FDA approved	
A2604	Celastrol	Chymotrypsin-like activity of the 20S proteasome (IC50=2.5 μ M)	Inhibitor	Selective	26000480; Cell; 2015		
A1933	Carfilzomib (PR-171)	Chymotrypsin-like activity of the 20S proteasome (IC50<5 nM)	Inhibitor	Selective	25482145; N Engl J Med; 2015	FDA approved	
A4011	ONX-0914 (PR-957)	20S proteasome LMP7 (IC50=10 nM)	Inhibitor	Selective	22341445; Cell; 2012		
A2585	MG-132	proteasome (IC50=100 nM)	Inhibitor	Pan	24710080; Nat Commun; 2014		
A2606	Epoxomicin	20s proteasome (N/A)	Inhibitor	Selective	18957208; Cell; 2008		
A4443	Gliotoxin	Chymotrypsin-like activity of the 20S proteasome (N/A)	Inhibitor	Selective	22936680; Angew Chem Int Ed Engl; 2012		
A4010	Salinosporamide A (NPI-0052, Marizomib)	Chymotrypsin-like activity of the 20S proteasome (IC50=3.5 nM); Trypsin-like activity of the 20S proteasome (IC50=28 nM)	Inhibitor	Selective	16286248; Cancer Cell; 2005	Phase 2	Multiple Myeloma
A1900	PSI	Chymotrypsin-like activity of the 20S proteasome (N/A)	Inhibitor	Selective	17823377; Circ Res; 2007		
A4007	MLN9708	Chymotrypsin-like activity of the 20S proteasome (IC50=3.4 nM, Ki=0.93 nM)	Inhibitor	Selective	23868105; Leukemia; 2014	Phase 3	Multiple Myeloma
A1934	Oprozomib (ONX-0912)	Chymotrypsin-like proteolytic (β 5) site of the 20S proteasome (IC50=36 nM); 20S proteasome LMP7 (IC50=82 nM)	Inhibitor	Selective	22995770; Autophagy; 2012	Phase 2	Multiple Myeloma; Hepatocellular Carcinoma
A2578	Clasto-Lactacystin β -lactone	proteasome(N/A)	Inhibitor	Pan	16719460; J Am Chem Soc; 2006		

For more product information, please check our website of <http://www.apexbt.com/research-area/proteases/proteasome.html>.

VEGFR Signaling Pathway




Hot products in VEGFR signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMD & Publication	Clinical trial	Condition
A8370	Axitinib (AG 013736)	VEGFR1/FLT1 (IC50=0.1 nM); VEGFR2/Fik1 (IC50=0.18 nM); VEGFR2/KDR (IC50=0.2 nM);	Inhibitor	Pan	25686603; Nature; 2015	FDA Approved	
A5467	Ponatinib (AP24534)	VEGFR2 (EC50=1.5 nM)	Inhibitor	Selective	24499222; N Engl J Med; 2014	FDA Approved	
A3009	Sorafenib	VEGFR2 (IC50=90 nM)	Inhibitor	Selective	24768112; Lancet; 2014	FDA Approved	
A8255	Sunitinib malate	VEGFR2/Fik1 (IC50=80 nM)	Inhibitor	Selective	23964934; N Engl J Med; 2013	FDA Approved	
A3022	Pazopanib (GW-786034)	VEGFR1/FLT1 (IC50=10 nM); VEGFR2 (IC50=30 nM); VEGFR3/Fit4 (IC50=47 nM)	Inhibitor	Selective	24785224; N Engl J Med; 2014	FDA Approved	
A8236	Regorafenib	VEGFR1/FLT1 (IC50=13 nM); mVEGFR2 (IC50=4.2 nM); mVEGFR3 (IC50=46 nM)	Inhibitor	Selective	23177515; Lancet; 2013	FDA Approved	
A8252	Nintedanib (BIBF 1120)	VEGFR1/FLT1 (IC50=34 nM); VEGFR2 (IC50=13 nM); VEGFR3/Fit4 (IC50=13 nM)	Inhibitor	Selective	24836310; N Engl J Med; 2014	FDA Approved	
A8555	Vandetanib (ZD6474)	VEGFR2 (IC50=40 nM)	Inhibitor	Selective	23924025; N Engl J Med; 2013	FDA Approved	
A5017	Motesanib Diphosphate (AMG-706)	VEGFR1/FLT1 (IC50=2 nM); VEGFR2 (IC50=3 nM); VEGFR3/Fit4 (IC50=6 nM)	Inhibitor	Selective	18596272; N Engl J Med; 2008	Phase 2	Gastrointestinal Cancer; Thyroid Cancer; Fallopien Tube Cancer
A8418	Dovitinib Dilactac acid	VEGFR1/FLT1 (IC50=10 nM); VEGFR2/Fik1 (IC50=13 nM); VEGFR3/Fit4 (IC50=8 nM)	Inhibitor	Selective	25981814; Lancet Oncol; 2015		
A1882	Cediranib (AZD2171)	VEGFR1/FLT1 (IC50=5 nM); VEGFR2/KDR (IC50=0.5 nM); VEGFR3/Fit4 (IC50 ≤3 nM)	Inhibitor	Selective	25218906; Lancet Oncol; 2014	Phase 3	Ovarian Cancer; Recurrent Glioblastoma; Metastatic Colorectal Cancer
A3969	Vatalanib	VEGFR1/FLT1 (IC50=77 nM); VEGFR2/KDR (IC50=37 nM);	Inhibitor	Selective	21464406; J Clin Oncol; 2011	Phase 3	
A8253	PD 173074	VEGFR2 (IC50=100-200 nM)	Inhibitor	Selective	24122810; Hepatology; 2014		

For more product information, please check our website of "http://www.apexbt.com/research-area/tyrosine-kinase/vegfr.html".

Canonical Wnt Signaling Pathway




Hot products in Canonical Wnt signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A1877	XAV-939	Wnt signaling (N/A)	Inhibitor	Pan	22610277; Nat Med; 2012		
A3413	FH535	Wnt signaling (N/A)	Inhibitor	Pan	23760401; Leukemia; 2014		
B7548	exo-IWR 1	Wnt signaling (N/A)	Inhibitor	Pan	19125156; Nat Chem Biol; 2009		
A8217	ICG 001	Wnt signaling (IC50=3 μM)	Inhibitor	Pan	23736280; EMBO J; 2013		

For more product information, please check our website of "<http://www.apexbt.com/research-area/stem-cell/wnt-signaling.html>".

Non-canonical Wnt Signaling Pathway



Hot products in Non-canonical Wnt signaling pathway

Cat. No	Product name	Target & IC50	Activity	Type	PMID & Publication	Clinical trial	Condition
A8685	Wnt-C59	Porcn (IC50=74 pM)	Inhibitor	Selective	23188502; Cancer Res; 2013		
A4529	JW 55	Wnt signaling (N/A)	Inhibitor	Pan	22440753; Cancer Res; 2012		
B5671	JW 67	Wnt signaling (IC50=1.17 μM)	Inhibitor	Pan	21199802; Cancer Res; 2011		
B5614	Cardionogen 1	Wnt signaling (EC50=23 nM)	Inhibitor	Pan	22195568; Chem Biol; 2011		

For more product information, please check our website of "<http://www.apexbt.com/research-area/stem-cell/wnt-signaling.html>".

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A1902	Z-VAD-FMK	Caspase	Inhibitor	Pan		
A8882	THZ1	CDK7 (IC50=3.2 nM)	Inhibitor	Selective		
A8950	UM 171	HSC	agonist			
A6001	3X FLAG Peptide					
A1910	Bromodomain Inhibitor, (+)-JQ1	BRD4(1/2) (IC50=77 nM/33 nM)	Inhibitor	Selective		
B1104	AZD-9291	EGFR (IC50=493.8 nM); Exon 19 deletion EGFR (IC50=12.92 nM); L858R/T790M EGFR (IC50=11.44 nM)	Inhibitor	Selective	Phase 3	Lung Cancer
A1901	Q-VD-OPh hydrate	Caspase	Inhibitor	Pan		
A8705	SCR7	DNA ligase IV	Inhibitor	Selective		
B5389	Mirin	ATM (IC50 = 12 µM)	Inhibitor	Selective		
A8705	SCR7	DNA ligase IV	Inhibitor	Selective		
A8883	SAR405	Vps34	Inhibitor	Selective		
A8329	R428	Axl (IC50 =14 nM)	Inhibitor	Selective		
A2585	MG-132	Proteasome(IC50=100 nM)	Inhibitor	Pan		
A3003	MDV3100 (Enzalutamide)	Androgen Receptor (IC50=36 nM)	Inhibitor	Pan	FDA approved	
A8167	Rapamycin (Sirolimus)	mTOR (IC50=0.1 nM)	Inhibitor	Pan	FDA approved	
B1274	AP20187	Fusion proteins containing a growth factor receptor signaling domain (N/A)	Activator	Pan		
A9503	BQU57	Ral	Inhibitor	Selective		
A3010	MK-2206 dihydrochloride	Akt1 (IC50=8 nM) ; Akt2 (IC50=12 nM) ; Akt3 (IC50=65 nM)	Inhibitor	Pan	Phase 2	Acute Megakaryoblastic Leukemia; Ovarian Sarcoma; Nasopharynx Carcinoma
A6002	FLAG tag Peptide	ATM (IC50 = 12 µM)	Inhibitor	Selective		
A3004	Vemurafenib (PLX4032, RG7204)	B-RafV600E (IC50=31 nM); C-Raf (IC50=48 nM)	Inhibitor	Selective	FDA approved	
A4006	MK-0752	γ-secretase (IC50=5 nM)	Inhibitor	Pan	Phase 2	Metastatic Breast Cancer
A8815	SM-164	XIAP (Ki=0.56 nM); c-IAP1 (Ki=0.31 nM); c-IAP2 (Ki=1.1 nM)	Inhibitor	Pan		
A8194	ABT-199	Bcl-2 (Ki<0.01 nM)	Inhibitor	Selective	Phase 3	Chronic Lymphocytic Leukemia
A3007	ABT-263	Bcl-2 (Ki≤1 nM); Bcl-xL (Ki≤0.5 nM); Bcl-w (Ki≤1 nM)	Inhibitor	Pan	Phase 2	Chronic Lymphoid Leukemia; Prostate Cancer
A8802	(S)-Crizotinib	MTH1 (IC50=72 nM)	Inhibitor	Pan	Phase 3	Non-Small Cell Lung Cancer

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A8173	Romidepsin (FK228, depsipeptide)	HDAC1 (IC50=36 nM); HDAC2 (IC50=47 nM)	Inhibitor	Selective	FDA approved	
A8183	Trichostatin A (TSA)	HDAC (IC50=1.8 nM)	Inhibitor	Pan		
A9502	OTS964	TOPK (IC50=28 nM)	Inhibitor	Selective		
A8239	CA-074 Me	Cathepsins B (IC50=36.3 nM)	Inhibitor	Selective		
A3008	Y-27632 dihydrochloride	ROCK1 (Ki =140 nM); ROCK2 (Ki =300 nM);	Inhibitor	Selective		
A2606	Epoxomicin	20s proteasome	Inhibitor	Selective		
A8192	Staurosporine (CGP 41251)	PKC (IC50 =3 nM); PKA (IC50 =7 nM); Receptor tyrosine kinases (IC50 =6 nM)	Inhibitor	Pan		
B3233	Z-LEHD-FMK	Caspase-8	Inhibitor	Selective		
A4154	Olaparib (AZD2281, Ku-0059436)	PARP1 (IC50=5 nM); PARP2 (IC50=1 nM)	Inhibitor	Selective	FDA approved	
A8895	P-Cresyl Sulfate					
A4180	SRT1720	SIRT1 (EC50=0.16 µM)	Activator	Selective		
A1905	3-Deazaneplanocin, DZNep	EZH2	Inhibitor	Selective		
B3232	Z-IETD-FMK	Caspase-8	Inhibitor	Selective		
A8660	Cilengitide	αvβ3 integrin (IC50 =4.1 nM); αvβ5 integrin (IC50 =79 nM)	Inhibitor	Selective	Phase 3	Glioblastoma
A1920	Z-DEVD-FMK	Caspase-3/-2/-6/-7/-8/-10	Inhibitor	Pan		
A2614	Bortezomib (PS-341)	20s proteasome (Ki=0.6 nM)	Inhibitor	Selective	FDA approved	
A3001	PCI-32765 (Ibrutinib)	BTK (IC50 =0.5 nM)	Inhibitor	Selective	FDA approved	
B4962	Thonzonium Bromide					
A8171	Entinostat (MS-275, SNDX-275)	HDAC1 (IC50=0.51 µM); HDAC3 (IC50=1.7 µM)	Inhibitor	Selective	Phase 3	Breast Cancer
B4168	AP1903				Phase 1	Castrate Resistant Prostate Cancer; Primary Immune Deficiency Disorders
A8003	Sulfo-NHS-LC-Biotin					
A3020	Crizotinib	c-Met (IC50=11 nM)	Inhibitor	Selective	FDA approved	
A3002	ABT-888 (Veliparib)	PARP1 (Ki=5.2 nM); PARP2 (Ki=2.9 nM)	Inhibitor	Selective	Phase 3	Breast Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer
A8952	UM 729	AhR antagonists	Activator	Selective		
A4084	Vorinostat (SAHA, MK0683)	HDAC	Inhibitor	Pan	FDA approved	

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A8193	ABT-737	Bcl-2 (EC50=30.3 nM); Bcl-xL (EC50=78.7 nM); Bcl-w (EC50=197.8 nM)	Inhibitor	Pan	Phase 2	Ovarian Cancer
A6004	Influenza Hemagglutinin (HA) Peptide					
A8890	HTH-01-015	NUAK1 (IC50=100 nM)	Inhibitor	Selective		
A8955	Z-YVAD-FMK	Caspase-1	Inhibitor	Selective		
A4050	GM 6001	MMP-1 (Ki=0.4nM); MMP-8 (Ki=0.1nM);MMP-9 (Ki=0.2nM)	Inhibitor	Pan		
N2833	Reutericyclin					
A3802	SCH 527123	CXCR1 (IC50 =42 nM); CXCR2 (IC50 =3 nM)	Inhibitor	Selective	Phase 2	Asthma; Chronic Obstructive Pulmonary Disease
B4894	SP2509	KDM1A (IC50 =13nM)	Inhibitor	Selective		
A3965	BI 2536	Plk1 (IC50=0.83 nM)	Inhibitor	Selective	Phase 2	Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Breast Cancer
A4135	Tofacitinib (CP-690550) Citrate	JAK1(IC50=112 nM); JAK2(IC50=20 nM); JAK3(IC50=1 nM)	Inhibitor	Selective	FDA approved	
A8694	AI-10-49	CBFβ –SMMHC and RUNX1 interaction (IC=260 nM)	Inhibitor	Selective		
A8336	KU-60019	ATM (IC50=6.3nM)	Inhibitor	Selective		
B1162	FRAX597	PAK1 (IC50 =8 nM); PAK2 (IC50 =13 nM); PAK3 (IC50 =19 nM)	Inhibitor	Pan		
A4083	Rocilinosat (ACY-1215)	HDAC6 (IC50=5 nM)	Inhibitor	Selective	Phase 2	Lymphoma; Multiple Myeloma
A3935	WEHI-539	Bcl-xL (IC50 = 1.1 nM)	Inhibitor	Selective		
A3762	RG7112	Mdm2-p53	Inhibitor	Pan	Phase 1	Neoplasms; Hematologic Neoplasms
B1383	VE-822	ATR (IC50=0.019 μM)	Inhibitor	Selective		
A8217	ICG 001	Wnt signaling (IC50=3 μM)	Inhibitor	Pan		
B1088	LY2606368	Chk1 (IC50=1.5 nM)	Inhibitor	Selective	Phase 1	Advanced Cancer
A8005	Sulfo-NHS-SS-Biotin					
B5246	740 Y-P	PI3k (IC50 =20 μM)	Activator	Pan		
B4888	Obeticholic Acid	FXR (EC50 =99 nM)	Activator	Selective	Phase 3	Primary Biliary Cirrhosis;
A4010	Salinosporamide A (NPI-0052, Marizomib)	Chymotrypsin-like activity of the 20S proteasome (IC50=3.5 nM); Trypsin-like activity of the 20S proteasome (IC50=28 nM)	Inhibitor	Selective	Phase 2	Multiple Myeloma

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A8221	EPZ-6438	EZH2 (IC50=11 nM, Ki=2.5 nM)	Inhibitor	Selective	Phase 2	Advanced Solid Tumors; B-cell Lymphomas
A3005	CAL-101 (Idelalisib, GS-1101)	PI3Kδ (IC50=2.5 nM)	Inhibitor	Selective	FDA approved	
A8708	Sephin1	PPP1R15A (N/A)	Inhibitor	Selective		
A3018	Trametinib (GSK1120212)	MEK1 (IC50=0.92 nM); MEK2 (IC50=1.8 nM)	Inhibitor	Selective	FDA approved	
A8348	LY2157299	TGF-βR1 (IC50 =56 nM)	Inhibitor	Selective	Phase 3	Myelodysplastic Syndromes
A8191	Nanaomycin A	DNMT3B (IC50 =500 nM)	Inhibitor	Selective		
A8002	NHS-Biotin					
A2577	Batimastat (BB-94)	MMP-1 (IC50=3 nM); MMP-2 (IC50=4 nM); MMP-9 (IC50=4 nM)	Inhibitor	Pan		
A8181	(-)-JQ1	BRD4 (IC50=10 μM)	Inhibitor	Selective		
A1903	E 64d	Cathepsin	Inhibitor	Pan		
A8346	BYL719	PI3Kα (IC50=5 nM)	Inhibitor	Selective	Phase 2	PIK3CA Mutated Advanced Solid Tumors
A4373	NLG919	IDO (Ki =7 nM)	Inhibitor	Selective		
A8200	DAPT (GSI-IX)	γ-secretase[Aβ] (IC50=20 nM)	Inhibitor	Selective		
A3736	PRT062607 Hydrochloride	Syk (IC50 =1 nM)	Inhibitor	Selective		
A9501	OTS514	TOPK (IC50=2.6 nM)	Inhibitor	Selective		
A4491	SGC-CBP30	CREBBP (IC50=21 nM); EP300 (IC50=38 nM)	Inhibitor	Selective		
A8182	3-Deazaneplanocin A (DZNep) hydrochloride	EZH2	Inhibitor	Selective		
A8179	MG-262	Chymotrypsin-like activity of the 20S proteasome	Inhibitor	Selective		
A4317	Apremilast (CC-10004)	PDE4 (IC50 =74 nM)	Inhibitor	Selective	FDA approved	
A3015	BKM120	PI3Kα (IC50=52 nM); PI3Kβ (IC50=166 nM); PI3Kδ (IC50=116 nM)	Inhibitor	Selective	Phase 3	Breast Cancer
B4881	UMI-77	Mcl-1 (Ki=490 nM)	Inhibitor	Selective		
A3021	GDC-0449 (Vismodegib)	Hedgehog (IC50 =3 nM)	Inhibitor	Pan	FDA approved	
A8001	Sulfo-NHS-Biotin					
A4227	Tipifarnib (Zarnestra)	Ftase (IC50 = 0.6 nM)	Inhibitor	Selective	Phase 3	Acute Myeloid Leukemia

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A4219	Birinapant (TL32711)	XIAP (Kd=45 nM); c-IAP1 (Kd<1 nM)	Inhibitor	Selective	Phase 2	Acute Myelogenous Leukemia; Ovarian Cancer
A3012	Ruxolitinib (INCB018424)	JAK1(IC50=3.3 nM); JAK2(IC50=2.8 nM)	Inhibitor	Selective	FDA approved	
B1052	HG-9-91-01	SIK1(IC50=0.92 nM); SIK2(IC50=6.6 nM); SIK3 (IC50=9.6 nM)	Inhibitor	Pan		
A1934	Oprozomib (ONX-0912)	Abc666	Inhibitor	Selective	Phase 2	Multiple Myeloma; Hepatocellular Carcinoma
B4948	UNC 2400	EZH1(IC50=62 μM); EZH1(IC50>200 μM)	Inhibitor	Selective		
A4192	SGI-1776 free base	Pim1 (IC50 =7 nM); Pim2 (IC50 =363 nM); Pim3 (IC50 =69 nM)	Inhibitor	Pan	Phase 1	Refractory Prostate and Lymphoma
A8169	Everolimus (RAD001)	mTOR (IC50=1.6-2.4 nM)	Inhibitor	Pan	FDA approved	
A1925	Caspase-3/7 Inhibitor I	Caspase-3 (Ki=60 nM); Caspase-7(Ki=170 nM)	Inhibitor	Selective		
A8207	AZD6244(Selumetinib)	MEK1 (IC50=14 nM)	Inhibitor	Selective	Phase 3	Metastatic Uveal Melanoma
B8023	Cerdulatinib	JAK	Inhibitor	Pan		
A4090	JNJ-26481585	HDAC1 (IC50=0.11 nM); HDAC2 (IC50=0.33 nM); HDAC11 (IC50=0.37 nM)	Inhibitor	Pan	Phase 2	Previously Treated Stage Ib-Iva Cutaneous T-cell Lymphoma
A8178	Panobinostat (LBH589)	HDAC	Inhibitor	Pan	FDA approved	
A8190	Semagacestat (LY450139)	Aβ42 (IC50 =10.9 nM); Aβ40 (IC50 =12.1 nM); Aβ38 (IC50 =12.0 nM)	Inhibitor	Pan	Phase 3	Alzheimer's Disease
B4877	URMC-099	MLK1 (IC50=19 nM); MLK2 (IC50=42 nM); MLK3 (14 nM)	Inhibitor	Pan		
A8312	Torin 1	mTOR1 (IC50=2 nM); mTOR2 (IC50=10 nM)	Inhibitor	Selective		
A8323	WP1130	Deubiquitinase (μSP5, μCH-L1, μSP9x, μSP14, μCH37)	Inhibitor	Selective		
A3811	SEA0400	Na ⁺ -Ca ²⁺ exchanger (IC50=5-33 nM)	Inhibitor	Selective		
A2575	Bestatin	Cytosol aminopeptidase (IC50=0,5 nM); Aminopeptidase N (IC50=5 nM); Zinc aminopeptidase (IC50=0.28 μM)	Inhibitor	Pan		
B5487	EHT 1864	Aβ	Inhibitor	Pan		
A8008	Biotin-HPDP					
A5047	Ivacaftor (VX-770)	F508del-CFTR(IC50= 25 nM) ; G551D-CFTR(IC50=100 nM)	Activator	Selective	Phase 3	Cystic Fibrosis
A1933	Carfilzomib (PR-171)	Chymotrypsin-like activity of the 20S proteasome (IC50< 5 nM)	Inhibitor	Selective	FDA approved	

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A8330	CX-4945(Silmitasertib)	CK2 (IC50=1 nM)	Inhibitor	Selective	Phase 1	Cholangiocarcinoma
A8330	CX-4945(Silmitasertib)	CK2 (IC50=1 nM)	Inhibitor	Selective	Phase 1	Cholangiocarcinoma
A3016	PLX-4720	B-RafV600E (IC50 =13 nM); C-Raf-1Y340D/Y341D (IC50 =6.7 nM)	Inhibitor	Selective		
A8464	LY2109761	TGF- β R1 (Ki =38 nM); TGF- β RII (Ki =300 nM)	Inhibitor	Selective		
A3013	PD0325901	MEK1/2 (IC50=0.33 nM)	Inhibitor	Selective	Phase 2	Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
B1036	MLN4924	NAE (IC50 =4 nM)	Inhibitor	Selective	Phase 1	Hematologic Malignancies; Multiple Myeloma; Lymphoma
B3209	Triapine	Ribonucleotide reductase	Inhibitor	Selective	Phase 2	Cervical Cancer or Vaginal Cancer
A4005	RO4929097	γ -secretase (IC50=4 nM); γ -secretase [A β 40] (IC50=14 nM) ; γ -secretase [Notch] (IC50=5 nM)	Inhibitor	Pan	Phase 2	Pancreatic Cancer; Colon Cancer
A8250	LY 294002	PI3K δ (IC50=0.57 nM)	Inhibitor	Selective		
A8246	BEZ235 (NVP-BEZ235)	PI3K α (IC50=4 nM); PI3K γ (IC50=5 nM); PI3K δ (IC50=7 nM)	Inhibitor	Selective	Phase 2	Pancreatic Neuroendocrine Tumors; Breast Cancer; Renal Cell Carcinoma
A2521	VE-821	ATR (IC50=26 nM)	Inhibitor	Selective		
A4240	Abiraterone	CYP3A4 (IC50 =30 nM)	Inhibitor	Selective	FDA approved	
A3006	GDC-0068 (RG7440)	Akt1 (IC50=5 nM); Akt2 (IC50=18 nM) Akt3 (IC50=8 nM)	Inhibitor	Pan	Phase 2	Gastric Cancer; Prostate Cancer
A4049	Marimastat	MMP-1 (IC50=5 nM); MMP-2 (IC50=6 nM); MMP-9 (IC50=3 nM)	Inhibitor	Selective	Phase 3	Breast Cancer; Lung Cancer
A4141	Baricitinib (LY3009104, INCB028050)	JAK1 (IC50 =5.9 nM); JAK2 (IC50 =5.7 nM); Tyk2 (IC50 =53 nM)	Inhibitor	Selective	Phase 3	Rheumatoid Arthritis
B4653	BV6	IAP (IC50=7.2 μ M)	Inhibitor	Selective		
A8412	Dinaciclib(SCH727965)	CDK1 (IC50=3 nM); CDK2 (IC50=1 nM); CDK5 (IC50=1 nM)	Inhibitor	Pan	Phase 3	Chronic Lymphocytic Leukemia
A2133	Saracatinib(AZD0530)	Abl (IC50=30 nM)	Inhibitor	Selective	Phase 3	Ovarian Cancer
A2576	E-64	Cathepsin	Inhibitor	Pan		
A8558	BI6727(Volasertib)	PLK1 (IC50 =0.87 nM); PLK2 (IC50 =5 nM); PLK3 (IC50 =56 nM)	Inhibitor	Pan	Phase 3	Acute Myeloid Leukaemia
A3347	Dabrafenib Mesylate (GSK-2118436)	B-Raf (IC50 =3.2 nM); B-RafV600E (IC50 =0.8 nM); C-Raf (IC50 =5.0 nM)	Inhibitor	Selective	FDA Approved	

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
B1579	JIB-04	JARID1A (IC50=230 nM); JMJD2A (IC50=445 nM); JMJD2B (IC50=435 nM)	Inhibitor	Pan		
A3840	ST 2825	MyD88	Inhibitor	Selective		
B4830	RGB-286638	CDK1/cyclin B1 (IC50=2 nM); CDK2/cyclin E (IC50=3 nM); CDK9/cyclin T1 (IC50=1 nM)	Inhibitor	Pan	Phase 1	Hematological Malignancies
B2303	Apalitinib	VEGFR2 (IC50=1 nM)	Inhibitor	Selective	FDA approved	
A3389	EMD638683	SGK1 (IC50=3 µM)	Inhibitor	Selective		
A4019	LY-411575	γ-secretase (membrane-based) (IC50=0.078 nM); γ-secretase (Aβ40) (IC50=0.082 nM); γ-secretase	Inhibitor	Selective		
A3446	GSK126	EZH2 (Ki =93 pM)	Inhibitor	Selective		
A4093	ITF2357 (Givinostat)	HDAC (IC50=7.5-16 nM)	Inhibitor	Pan	Phase 2	Myeloproliferative Diseases; Hodgkin's Lymphoma
A8210	GDC-0941	PI3Kα (IC50=3 nM); PI3Kβ (IC50=33 nM); PI3Kδ (IC50=3 nM)	Inhibitor	Selective	Phase 2	Breast Cancer; Non-Squamous Non-Small Cell Lung Cancer
A2700	10Panx	Panx-1	Inhibitor	Selective		
A8254	SB 203580	p38α MAPK (IC50 =0.3–0.5 µM)	Inhibitor	Selective		
B4672	INT-777	JAK1(IC50=112 nM); JAK2(IC50=20 nM); JAK3(IC50=1 nM)	Activator	Selective		
A4143	CYT387	JAK1(IC50=11 nM); JAK2(IC50=18 nM); JAK3(IC50=155 nM)	Inhibitor	Selective	Phase 3	Myelofibrosis
B1536	AZD1080	GSK-3α (Ki=6.9 nM); GSK-3β (Ki=31 nM)	Inhibitor	Selective		
A4095	Pracinostat (SB939)	HDAC1 (IC50=49 nM); HDAC3 (IC50=43 nM); HDAC5 (IC50=47 nM)	Inhibitor	Pan	Phase 2	Myeloproliferative Disorders
B3179	PTC-209	BMI-1 (IC50=0.5 µM)	Inhibitor	Selective		
A4153	BMN 673	PARP1 (Ki=1.2 nM); PARP2 (Ki=0.9 nM)	Inhibitor	Pan	Phase 3	Breast Neoplasms
A3556	LKB1 (AAK1 dual inhibitor)	Pim1 (Kd =35 nM)	Inhibitor	Selective		
A1044	Gap 26					
B7023	MK 571	CysLT1 [LTD4] (EC50 =1.3 nM)	Inhibitor	Selective		
A3860	Tasquinimod				Phase 3	Prostate Cancer
A8370	Axitinib	VEGFR1/FLT1 (IC50=0.1 nM); VEGFR2/Flk1 (IC50=0.18 nM); VEGFR2/KDR (IC50=0.2 nM);	Inhibitor	Pan	Phase 3	Carcinoma, Pancreatic Ductal; Kidney Neoplasms
A4521	TCS PIM-1 1	Pim-1 (IC50=50 nM)	Inhibitor	Selective		

Hot Products

Cat. No	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
A8698	SP-2509	KDM1A (IC50 =13 nM)	Inhibitor			
B4964	(-)-epicatechin				Phase 4	Cardiovascular Disease;Cancer
A4110	MLN8237 (Alisertib)	Aurora A (IC50=1.2 nM)	Inhibitor	Selective	Phase 3	Relapsed Peripheral T-Cell Lymphoma
A4032	VX-222	NS5B (IC50 =0.94-1.2 µM)	Inhibitor	Selective	Phase 2	Chronic Hepatitis C Virus
A8634	WEHI-539 hydrochloride	Bcl-xL (IC50 = 1.1 nM)	Inhibitor	Selective		
A3023	P005091	USP7 (EC50=4.2 µM)	Inhibitor	Selective		
A4057	AUY922 (NVP-AUY922)	Hsp90α (13 nM); Hsp90β (21 nM)	Inhibitor	Selective	Phase 2	Breast Cancer; Non-small-cell Lung Cancer
A8212	PR-619	USP2 (EC50=7.2 µM); USP4 (EC50=3.93 µM); USP20 (EC50=5.10 µM)	Inhibitor	Pan		
A1124	Amyloid β-Peptide (1-40) (human)					
B4754	LDC000067	CDK1(IC50=125 nM); CDK2(IC50=55 nM); CDK9(IC50=49 nM)	Inhibitor	Pan		
A8006	NHS-SS-Biotin					
A4101	Tubastatin A	HDAC6 (IC50=15 nM)	Inhibitor	Selective		
A4011	ONX-0914 (PR-957)	20S proteasome LMP7 (IC50=10 nM)	Inhibitor	Selective		
A3503	IRAK inhibitor 4	IRAK	Inhibitor	Pan		
B4965	(-)-epicatechin gallate				Phase 4	Cognitive Function; Mood
B4966	(-)-epigallocatechin				Phase 2	Mild to Moderately Active Ulcerative Colitis
A8309	Perifosine	Akt (IC50=4.7 µM)	Inhibitor	Pan	Phase 3	Colorectal Cancer
A6005	V5 Epitope Tag Peptide					
A8353	3-Methyladenine	Vps34 (IC50=25 µM); PI3Kγ (IC50=60 µM)	Inhibitor	Selective		
B6226	Kainic acid					
A3194	AST 487	FLT3	Inhibitor	Selective		
B3686	DMH-1	ALK1 (IC50 =27 nM); ALK2 (IC50 =107.9 nM); ALK3(IC50 <5 nM)	Inhibitor	Pan		
A3692	OTX-015	BRD2 (EC50=10-19 nM); BRD3 (EC50=10-19 nM); BRD4 (EC50=10-19 nM)	Inhibitor	Pan	Phase 2	Glioblastoma Multiforme
A2701	Scrambled 10Panx	Panx-1	Inhibitor	Selective		

Hot Products

Cat. N°	Product name	Target & IC50	Activity	Type	Clinical trial	Condition
B1255	AZ505	SMYD2 (IC50=0.12 µM) (Ki=0.3 µM)	Inhibitor	Selective		
A8351	VX-809	F508 del CFTR (EC50 =0.1 µM)	Activator	Selective	Phase 2	Cystic Fibrosis
B4806	Brivaracetam	Sodium Channel	Inhibitor	Selective	Phase 3	Epilepsy
A4103	LAQ824 (NVP-LAQ824, Dacinostat)	HDAC (IC50=32 nM)	Inhibitor	Pan		
A8236	Regorafenib	VEGFR1/FLT1 (IC50=13 nM); mVEGFR2 (IC50=4.2 nM); mVEGFR3 (IC50=46 nM)	Inhibitor	Selective	FDA approved	
A4383	Tolcapone	COMT (IC50 = 36 nM)	Inhibitor	Selective	FDA Approved	
A1185	BMS-754807	BMS-754807	Inhibitor	Selective	Phase 2	Breast Cancer
A3608	MK 0893	Glucagon Receptor (IC50 =6.6 nM)	Inhibitor	Pan	Phase 2	Diabetes Mellitus, Type 2
A3828	Sobetirome	Thyroid hormone β -receptor	Activator	Selective	Phase 1	X-Linked Adrenoleukodystrophy; Adrenomyeloneuropathy
A4102	CI994 (Tacedinaline)	HDAC1 (IC50=0.57 µM)	Inhibitor	Selective	Phase 2	Multiple Myeloma
A8315	NU7441 (KU-57788)	DNA-PK (IC50 =14 nM)	Inhibitor	Selective		
A4096	Belinostat (PXD101)	HDAC (IC50=27 nM)	Inhibitor	Pan	FDA approved	
A3017	Dasatinib (anhydrous)	Abl (IC50=0.6 nM); Src (IC50=0.8 nM); c-Kit (WT)/c-Kit (D816V) (IC50=79 nM/37 nM)	Inhibitor	Selective	FDA Approved	
B5084	DL-TBOA	EAAT (IC50=170 µM); EAAT2 (IC50=6 µM); EAAT3 (IC50=6 µM)	Inhibitor	Pan		
A8337	CX-5461	Pol I (IC50=142 nM)	Inhibitor	Selective		
B2266	LDE225 (NVP-LDE225, Erismodegib)	Smoothened (IC50 =2.5/1.3 nM)	Inhibitor	Selective	Phase 2	PTCH1 or SMO Mutated Tumors; Basal Cell Carcinoma; Medulloblastoma

Worldwide Distributors



USA (Headquarter)

ApexBio Technology LLC
Tel: +1-832-696-8203/+1-855-577-7998
Fax: +1-832-641-3177
Email: sales@apexbt.com
Website: www.apexbt.com



USA (Headquarter)

CliniSciences
Tel: +33 9 77 40 09 09
Fax: +33 9 77 40 10 11
Email: info@clinisciences.com
Website: www.clinisciences.com



Australia

Assay Matrix Pty Ltd
Tel: +61 405 701 981
Fax: +61 3 8678 3150
Email: info@assaymatrix.com
Website: www.assaymatrix.com



Germany

GENTAUR GmbH
Tel: +0241 40 08 90 86
Fax: +0241 55 91 05 36
Email: de@gentaur.com
Website: www.gentaur.com



Belgium

GENTAUR Belgium BVBA BE0473327336
Tel: +0032 16 58 90 45
Fax: +0032 16 50 90 45
Email: lieven@gentaur.com
Website: www.gentaur.com



India

BR Biochem Life Sciences Pvt. Ltd
Tel: +91-11-43033662,43033664
Fax: +91-11-42342334
Email: info@brbls.com
Website: http://www.brbls.com



Italy

CliniSciences
Tel: +39 3492832940
Email: italia@clinisciences.com
Website: www.clinisciences.com

Biolink India

Tel: (+91)-11-45035753
Fax: (+91)-11-45035753
Email: customerservice@biolinkk.com
Website: http://www.biolinkk.com



China

ShangHai WeiHuan Biotech Co.,Ltd
Tel: +86-400-656-3080
Fax: +86-556-695-83
Email: sales@wheybio.com
Website: www.wheybio.com



Demark

SMS-gruppen
Tel: +45 45 86 44 00
Fax: +45 45 86 48 81
Email: mail@sms-gruppen.dk
Website: www.sms-gruppen.dk



Israel

A2S technologies Ltd
Tel: 077-5567681
Fax: 077-5567682
Email: isaac@a2s.co.il
Website: www.a2s.co.il



Japan

Kokusai Kinzoku Yakuhin Co.,Ltd
Tel: 03-3400-1939
Fax: 03-3486-6509
Email: ota@kkyc.co.jp
Website: www.kkyc.co.jp

Worldwide Distributors



Spain

EURODIAGNOSTICO S.L
Tel: +34 91 3824640
Fax: +34 91 3824632
Email: info@eurodiagnostico.com
Website: www.eurodiagnostico.com

GENTAUR Spain
Tel: +0911876558
Email: spain@gentaur.com
Website: www.gentaur.com

CliniSciences
Tel: +34 512 702 901
Email: espana@clinisciences.com
Website: www.clinisciences.com



United Kingdom

Bioquote Limited
Tel: 00 44 1904 431402
Fax: 00 44 1904 431409
Email: sales@bioquote.com
Website: www.bioquote.com

(Peptides and Amino Acids Products)
Stratech Scientific Limited
Tel: +44(0) 1638 782600
Fax: +44(0) 1638 782606
Email: info@stratech.co.uk
Website: www.stratech.co.uk

Generon(A CliniSciences Company)
Tel: +44 (0)1753 866 511
Fax: +44 (0)1753 208 899
Email: info@generon.co.uk
Website: www.generon.co.uk



Korea

**Technical & Marketing
Division of Bioclone Corp.**
Tel: +82-2-2690-0058
Fax: +82-2-2690-0397
Email: bioclone@bioclone.co.kr
Website: www.bioclone.co.kr



Netherlands

GENTAUR Nederland BV
Tel: +0208-080893
Fax: +0497-517897
Email: nl@gentaur.com
Website: www.gentaur.com



Singapore

Vector Biomed Pte Ltd
Tel: +65 8290 4412
Email: sales@vbm.com.sg
Website: www.vbm.com.sg



Sweden

SMS-gruppen
Tel: 042 - 12 02 40
Fax: +45 45 86 48 81
Email: mail@sms-gruppen.se
Website: www.sms-gruppen.se

Please checkout our website for the distributors in your regions:



Egypt



Estonia



Finland



Iceland



Ireland



Iraq



Jordan



Saudi Arabia



Kuwait



Latvia



Lebanon



Lithuania



Morocco



Norway



New Zealand



Poland



Qatar



Taiwan




Tunisia



Turkey



UAE



Address: 7505 Fannin street, Suite 210, Houston, TX 77054

Sales Department: sales@apexbt.com

General Enquiries: info@apexbt.com

Tech Support: support@apexbt.com

Telephone: +1-832-696-8203

Fax: +1-832-641-3177